WO2016126876A3 - Listeria-based adjuvants - Google Patents

Listeria-based adjuvants Download PDF

Info

Publication number
WO2016126876A3
WO2016126876A3 PCT/US2016/016452 US2016016452W WO2016126876A3 WO 2016126876 A3 WO2016126876 A3 WO 2016126876A3 US 2016016452 W US2016016452 W US 2016016452W WO 2016126876 A3 WO2016126876 A3 WO 2016126876A3
Authority
WO
WIPO (PCT)
Prior art keywords
listeria
based adjuvants
methods
disclosure
transplant
Prior art date
Application number
PCT/US2016/016452
Other languages
French (fr)
Other versions
WO2016126876A2 (en
Inventor
Robert Petit
Original Assignee
Advaxis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis, Inc. filed Critical Advaxis, Inc.
Publication of WO2016126876A2 publication Critical patent/WO2016126876A2/en
Publication of WO2016126876A3 publication Critical patent/WO2016126876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
PCT/US2016/016452 2015-02-03 2016-02-03 Listeria-based adjuvants WO2016126876A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111147P 2015-02-03 2015-02-03
US62/111,147 2015-02-03

Publications (2)

Publication Number Publication Date
WO2016126876A2 WO2016126876A2 (en) 2016-08-11
WO2016126876A3 true WO2016126876A3 (en) 2016-10-27

Family

ID=56564870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/016452 WO2016126876A2 (en) 2015-02-03 2016-02-03 Listeria-based adjuvants

Country Status (1)

Country Link
WO (1) WO2016126876A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
JP2015511602A (en) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド Inhibition of suppressor cell function after Listeria vaccine treatment
BR112016019057A2 (en) 2014-02-18 2017-10-10 Advaxis Inc method of inducing an immune response against a disease in an individual
CN106459887A (en) 2014-04-24 2017-02-22 阿德瓦希斯公司 Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
WO2017106638A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
EP3548623A4 (en) 2016-11-30 2020-11-25 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALPDOGAN, 0. ET AL.: "Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.", BLOOD, vol. 105, no. 2, 2005, pages 865 - 873, XP002604499 *
MACIAG, P. C. ET AL.: "The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.", VACCINE, vol. 27, no. 30, 2009, pages 3975 - 3983, XP026153147 *
ROBACK, J. D.: "Vaccine-enhanced donor lymphocyte infusion (veDLI).", ASH EDUCATION PROGRAM BOOK, vol. 2006, no. 1, 2006, pages 486 - 491, XP055324970 *
SEGGEWISS, R. ET AL.: "Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update.", vol. 115, no. 19, 2010, pages 3861 - 3868, XP055324979 *
ZAKRZEWSKI, J. L. ET AL.: "Adoptive transfer of T- cell precursors enhances T- cell reconstitution after allogeneic hematopoietic stem cell transplantation.", NATURE MEDICINE, vol. 12, no. 9, 2006, pages 1039 - 1047, XP055324976 *

Also Published As

Publication number Publication date
WO2016126876A2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
WO2016126876A3 (en) Listeria-based adjuvants
HK1255296A1 (en) Crispr/cas-related methods and compositions for improving transplantation
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2012125551A8 (en) Listeria-based adjuvants
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP3176794A4 (en) Rapidly-quenched alloy and preparation method for rare-earth magnet
EP3484509A4 (en) Compositions and methods for flavivirus vaccination
EP3113798A4 (en) Methods and compositions for modifying the immune response
MY173901A (en) Compositions and methods of enhancing immune responses to enteric pathogens
HK1250637A1 (en) Agents and compositions for eliciting an immune response
GB201715769D0 (en) Methods, Compositions and uses relating thereto
EP3518976A4 (en) Compositions and methods for improving immune system function
GB201715768D0 (en) Methods, compositions and uses relating thereto
WO2016079110A3 (en) Use of enzyme for cleaning
GB201706349D0 (en) Methods, compositions and uses relating thereto
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
EP3368547A4 (en) Chimeric rsv, immunogenic compositions, and methods of use
WO2017011769A3 (en) Il-17f-specific capture agents, compositions, and methods of using and making
EP3324963A4 (en) Methods and compositions for enhancing immune response to vaccination
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers
IL272956A (en) Methods and compositions for preparing surfactant protein d (sp-d)
IL272955A (en) Methods, compositions and cells for preparing surfactant protein d (sp-d)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16747232

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16747232

Country of ref document: EP

Kind code of ref document: A2